Damora Therapeutics Inc.
DMRA | NASDAQ
$22.20
-$0.65 (-2.84%)
Sep 22, 2026, 2:33 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 79K | 68K | n/a | 5K | 65K | 142K | 240K | 464K | 771K | 789K | 830K | 765K | 502K | 511K | 490K | 437K | 451K | 459K | 440K | 381K | 345K | 233K |
Gross Profit | -79K | -68K | n/a | -5K | -65K | -142K | -240K | -464K | -771K | -789K | -830K | -765K | -502K | -511K | -490K | -437K | -451K | -459K | -440K | -381K | -345K | -233K |
Operating Income | -270.66M | -239.08M | -210.87M | -11.88M | -12.57M | -13.76M | -16.9M | -20.14M | -22.16M | -28.71M | -36.46M | -44.03M | -51.8M | -57.76M | -61.21M | -61.15M | -60.47M | -55.61M | -52.23M | -50.06M | -47.29M | -35.02M |
Interest Income | 8.17M | 4.16M | 1.17M | 394K | 498K | 661K | 844K | 956K | 1.28M | 1.51M | 1.69M | 1.63M | 1.38M | 1.1M | 722K | 468K | 282K | 178K | 156K | 126K | 91K | 39K |
Pretax Income | -262.49M | -235M | -209.79M | -15.85M | -16.59M | -18.45M | -21.4M | -21.12M | -25.38M | -30.83M | -38.35M | -45.94M | -51.54M | -57.68M | -61.62M | -60.96M | -59.93M | -55.35M | -51.75M | -49.92M | -48.88M | -36.57M |
Net Income | -262.83M | -235.09M | -209.84M | -15.84M | -16.59M | -18.5M | -21.44M | -21.17M | -25.43M | -30.83M | -38.35M | -45.94M | -51.54M | -57.68M | -61.62M | -60.96M | -59.93M | -55.35M | -51.75M | -49.92M | -48.88M | -36.57M |
Selling & General & Admin | 22.29M | 14.8M | 9.69M | 7.31M | 8.26M | 9M | 10.26M | 11.52M | 11.77M | 12.05M | 11.86M | 11.49M | 11.58M | 11.92M | 12.51M | 13.16M | 13.21M | 13.42M | 13.3M | 13.55M | 12.91M | 9.39M |
Research & Development | 248.36M | 224.29M | 201.19M | 4.57M | 4.24M | 4.61M | 6.4M | 8.16M | 9.62M | 15.87M | 23.77M | 31.77M | 39.72M | 45.33M | 48.21M | 47.55M | 46.81M | 41.73M | 38.49M | 36.13M | 34.03M | 25.39M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 270.58M | 239.02M | 210.87M | 11.88M | 12.5M | 13.61M | 16.66M | 19.68M | 21.39M | 27.92M | 35.63M | 43.27M | 51.3M | 57.25M | 60.72M | 60.71M | 60.02M | 55.16M | 51.79M | 49.68M | 46.94M | 34.79M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 270.66M | 239.08M | 210.87M | 11.88M | 12.57M | 13.76M | 16.9M | 20.14M | 22.16M | 28.71M | 36.46M | 44.03M | 51.8M | 57.76M | 61.21M | 61.15M | 60.47M | 55.61M | 52.23M | 50.06M | 47.29M | 35.02M |
Income Tax Expense | 341K | 90K | 50K | -2K | 5K | 43K | 41K | 49K | 42K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 61.14M | 34.3M | 1.66M | 1.33M | 1.32M | 1.32M | 1.29M | 1.14M | 1.08M | 1.08M | 1.08M | 1.08M | 1.06M | 1.03M | 1.03M | 1.02M | 1.01M | 1.01M | 1.01M | 1.01M | 1.01M | 1.01M |
Shares Outstanding (Diluted) | 61.14M | 34.3M | 1.66M | 1.33M | 1.32M | 1.32M | 1.29M | 1.14M | 1.08M | 1.08M | 1.08M | 1.08M | 1.06M | 1.03M | 1.03M | 1.02M | 1.01M | 1.01M | 1.01M | 1.01M | 1.01M | 1.01M |
EPS (Basic) | -124.78 | -126.87 | -127.98 | -12.10 | -13.13 | -15.45 | -18.58 | -19.33 | -23.44 | -28.70 | -36.30 | -44.05 | -50.01 | -56.54 | -60.65 | -60.20 | -59.30 | -54.76 | -51.21 | -41.83 | -43.49 | -31.32 |
EPS (Diluted) | -124.78 | -126.87 | -127.98 | -12.10 | -13.13 | -15.45 | -18.58 | -19.33 | -23.44 | -28.70 | -36.30 | -44.05 | -50.01 | -56.54 | -60.65 | -60.20 | -59.30 | -54.76 | -51.21 | -41.83 | -43.49 | -31.32 |
EBITDA | -266.46M | -234.91M | -209.76M | -15.81M | -16.51M | -18.3M | -21.16M | -20.66M | -24.61M | -30.04M | -37.52M | -45.18M | -51.04M | -57.17M | -61.13M | -60.53M | -59.48M | -54.89M | -51.52M | -49.47M | -46.98M | -34.79M |
EBIT | -266.56M | -235M | -209.79M | -15.85M | -16.59M | -18.45M | -21.4M | -21.12M | -25.38M | -30.83M | -38.35M | -45.94M | -51.54M | -57.68M | -61.62M | -60.96M | -59.93M | -55.35M | -51.96M | -49.85M | -47.32M | -35.02M |
Depreciation & Amortization | 96K | 94K | 34K | 32K | 82K | 150K | 240K | 464K | 771K | 789K | 830K | 765K | 502K | 511K | 490K | 437K | 451K | 459K | 440K | 381K | 345K | 233K |
Add to Watchlist
Select watchlists to add or remove DMRA